GlassScriptPhysician profile
Reni Joseph
NPI 1558836437
$825.50
in general payments reported to CMS, 2019-2025
19 companies · $31.35 in 2025
The $31.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $189 · 2023: $75.02 · 2024: $66.61 · 2025: $31.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.48 | 2021-2023 | |
| Seagen INC. | $110.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $64.03 | 2021-2023 | Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $62.08 | 2021 | |
| Lilly USA, LLC | $52.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $50.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.56 | 2021-2024 | |
| Novo Nordisk INC | $35.48 | 2022-2023 | Wegovy |
| Pfizer INC. | $29.13 | 2021-2025 | |
| Janssen Biotech, INC. | $26.02 | 2024 | Akeega, Erleada, Rybrevant |
| Daiichi Sankyo INC. | $22.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.71 | 2021 | |
| Amgen INC. | $16.54 | 2025 | Otezla, Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.37 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.00 | 2021 | |
| Glaxosmithkline, LLC. | $12.77 | 2023 | Flulaval Quadrivalent, Shingrix |
| Merck Sharp & Dohme LLC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reni Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.